Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Athiththan YogeswaranDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.ORCID https://orcid.org/0000-0001-9505-8608
Meike FünderichDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.
Katharina WendlandtDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.
Jeffrey S AnnisDivision of Cardiovascular Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Evan BrittainDivision of Cardiovascular Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Christina A EichstaedtCenter for Pulmonary Hypertension Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital and Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL) Heidelberg Germany.
Ekkehard GrünigCenter for Pulmonary Hypertension Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital and Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL) Heidelberg Germany.
Andrew J SweattDivision of Pulmonary, Allergy, and Critical Care, Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University Stanford California USA.
Roham T ZamanianDivision of Pulmonary, Allergy, and Critical Care, Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University Stanford California USA.
Friedrich GrimmingerDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.
Jochen WilhelmDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.
Hossein-Ardeschir GhofraniDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.
Khodr TelloDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.ORCID https://orcid.org/0000-0002-5557-623X
Werner SeegerDepartment of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL) Giessen Germany.ORCID https://orcid.org/0000-0003-1946-0894
PVRI GoDeep Consortium
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
In 567 PH-COPD patients from the PVRI GoDeep Meta-Registry, ACE inhibitor use was associated with improved survival only in severe PH (PVR > 5 WU), supporting prospective trials targeting this high-risk subgroup.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Angiotensin Converting Enzyme Inhibition and Mortality in Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD). · full record | OpenQuestion